Crinetics Pharmaceuticals Inc (CRNX):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Crinetics Pharmaceuticals Inc (CRNX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8089
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:26
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Crinetics Pharmaceuticals Inc (Crinetics) is a developer of novel therapeutics targeting peptide hormone receptors for the treatment of rare endocrine disorders and endocrine-related cancers. The company’s products include neuropeptides and their receptors, orally-available somatostatin agonists, and orally available kisspeptin antagonists. Its neuropeptides controls aspects of human development, physiology and oncogenesis. Crinetics provides somatostatin agonists for the treatment of pancreatic neuroendocrine tumors, carcinoid tumors, GH secreting adenomas, diabetic retinopathy, graves ophthalmopathy, chronic pain, epilepsy, and dementia; and kisspeptin antagonists for the treatment of endometriosis, uterine fibroids, and PCOS. The company provides endocrine drug discovery and development through collaboration with healthcare and research institutes. Crinetics is headquartered in San Diego, California, the US.

Crinetics Pharmaceuticals Inc (CRNX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Crinetics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Crinetics Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Crinetics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Crinetics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Crinetics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Crinetics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Crinetics Pharma Raises USD63.5 Million in Series B Financing 10
Crinetics Pharma Raises USD40 Million in Series A Financing Round 12
Equity Offering 13
Crinetics Pharma Raises USD117.3 Million in IPO of Shares 13
Crinetics Pharmaceuticals Inc – Key Competitors 14
Crinetics Pharmaceuticals Inc – Key Employees 15
Crinetics Pharmaceuticals Inc – Locations And Subsidiaries 16
Head Office 16
Recent Developments 17
Financial Announcements 17
Aug 30, 2018: Crinetics Pharmaceuticals reports second quarter 2018 financial results and provides corporate update 17
Corporate Communications 18
Jun 18, 2018: Crinetics Pharmaceuticals Names Alan Krasner As Chief Medical Officer 18
Jan 04, 2018: Crinetics Pharmaceuticals Appoints Marc Wilson as Chief Financial Officer 19
Government and Public Interest 20
Apr 28, 2018: Crinetics Pharmaceuticals Awarded NIH Phase-I SBIR Grant to Develop Somatostatin Receptor Agonist Drugs for Ophthalmic Diseases 20
Product News 21
07/13/2017: Crinetics Pharmaceuticals Awarded $2.8 Million SBIR Grant to Support Development of Acromegaly Drug Candidate CRN00808 21
06/21/2018: Crinetics Pharmaceuticals Awarded up to $3.2 Million in SBIR Grants for Acromegaly 22
03/12/2018: Crinetics Pharmaceuticals Announces Presentation on Hyperinsulinemia Drug Candidate at ENDO 2018 23
Clinical Trials 24
Mar 12, 2018: Crinetics Pharmaceuticals Announces Upcoming Presentation on Acromegaly Drug Candiadate CRN00808 at ENDO 2018 24
Oct 26, 2017: Crinetics Pharmaceuticals Initiates Phase 1 Study of Lead Candidate CRN00808 for Acromegaly 25
Appendix 26
Methodology 26
About GlobalData 26
Contact Us 26
Disclaimer 26

List of Tables
Crinetics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Crinetics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Crinetics Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Crinetics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Crinetics Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Crinetics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Crinetics Pharma Raises USD63.5 Million in Series B Financing 10
Crinetics Pharma Raises USD40 Million in Series A Financing Round 12
Crinetics Pharma Raises USD117.3 Million in IPO of Shares 13
Crinetics Pharmaceuticals Inc, Key Competitors 14
Crinetics Pharmaceuticals Inc, Key Employees 15

List of Figures
Crinetics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Crinetics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Crinetics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Crinetics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Crinetics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Crinetics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Crinetics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Crinetics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Crinetics Pharmaceuticals Inc (CRNX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Acumen Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary Acumen Pharmaceuticals Inc (Acumen) is a pharmaceutical company that discovers and develops therapeutics and diagnostics services for the treatment of Alzheimer’s disease and other related neurodegenerative conditions. It focuses on development of ADDL (amyloid-beta derived diffusible ligand …
  • EpiVax Inc-製薬・医療分野:企業M&A・提携分析
    Summary EpiVax Inc (EpiVax) is an immunology company which develops analytical capabilities in the field of computational immunology. Its product pipeline includes Tregitopes; deimmunization projects including deimmunized botox and deimmunized FVIII; and biodefense vaccines. Tregitopes are linear se …
  • Polaris Infrastructure Inc (PIF):企業の財務・戦略的SWOT分析
    Summary Polaris Infrastructure Inc (Polaris Infrastructure), formerly Ram Power Corp is a renewable energy company that explores, acquires, operates and develops geothermal energy projects in Latin America. The company owns and operates San Jacinto Tizate Geothermal project, which is located in nort …
  • Oxford Biodynamics Plc:製薬・医療:M&Aディール及び事業提携情報
    Summary Oxford Biodynamics Plc (Oxford Biodynamics) is a developer of biomarker discovery platform. The company concentrates on research in detection, monitoring and prognosis of major diseases associated with aberrant gene expression such as oncology, metabolic, inflammatory, cardiovascular and neu …
  • ALS Ltd (ALQ):企業の財務・戦略的SWOT分析
    ALS Ltd (ALQ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Ricoh Company, Ltd.:企業の戦略・SWOT・財務情報
    Ricoh Company, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Ricoh Company, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Bellerophon Therapeutics Inc (BLPH):製薬・医療:M&Aディール及び事業提携情報
    Summary Bellerophon Therapeutics Inc (Bellerophon Therapeutics), formerly Bellerophon Therapeutics LLC is a clinical-stage biotherapeutics company that focuses on the development of therapies for the treatment of cardiopulmonary diseases. The company’s lead investigational cardiopulmonary product ca …
  • Aevi Genomic Medicine Inc (GNMX)-製薬・医療分野:企業M&A・提携分析
    Summary Aevi Genomic Medicine Inc (Aevi), formerly Medgenics Inc is a research and development company that discovers and develops novel therapies for pediatric onset and life-altering diseases.The company’s pipeline products include AEVI-001 and AEVI-002. Its lead product AEVI-001, is a glutamaterg …
  • Television Francaise 1 SA (TFI):企業の財務・戦略的SWOT分析
    Television Francaise 1 SA (TFI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Neuland Laboratories Ltd (NEULANDLAB):企業の財務・戦略的SWOT分析
    Summary Neuland Laboratories Ltd (Neuland Lab), a subsidiary of Neuland Health Sciences Pvt Ltd is an API manufacturing service provider that manufactures active pharmaceutical ingredients, advanced intermediates; and offers chemistry related services. The company provides APIs in various therapeuti …
  • Thrive Bioscience Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Thrive Bioscience Inc (Thrive Bioscience) is a life science company that provides automated non-microbial cell culture instruments. The company’s cell culture systems provide scalable cell propagation, analytics, reproducible protocols, and complete process history documentation with the ima …
  • Public Power Corporation SA (PPC):企業の財務・戦略的SWOT分析
    Public Power Corporation SA (PPC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • EnPro Industries, Inc.:企業のM&A・事業提携・投資動向
    EnPro Industries, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's EnPro Industries, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • CiCi Enterprises, LP:企業の戦略・SWOT・財務情報
    CiCi Enterprises, LP - Strategy, SWOT and Corporate Finance Report Summary CiCi Enterprises, LP - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Bsquare Corporation (BSQR):企業の財務・戦略的SWOT分析
    Bsquare Corporation (BSQR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Fred’s Inc:企業の戦略・SWOT・財務情報
    Fred's Inc - Strategy, SWOT and Corporate Finance Report Summary Fred's Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • DormaKaba Holding AG:企業の戦略・SWOT・財務情報
    DormaKaba Holding AG - Strategy, SWOT and Corporate Finance Report Summary DormaKaba Holding AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Checkpoint Surgical Inc:医療機器:M&Aディール及び事業提携情報
    Summary Checkpoint Surgical Inc (Checkpoint Surgical) is a medical device company that offers neuro-protective surgical devices. The company’s products include checkpoint stimulators and locators; and checkpoint head and neck systems. Its checkpoint stimulators and locators provide biphasic stimulat …
  • leon-nanodrugs GmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary Leon-Nanodrugs GmbH (Leon-Nanodrugs) is a drug development company that discovers and develops nanotechnology based drug delivery systems. The company develops oral and parenteral products. Its products portfolio includes nanoparticles and drug-delivery-systems such as functionalized multila …
  • Bioanalytical Systems, Inc.:企業の戦略・SWOT・財務情報
    Bioanalytical Systems, Inc. - Strategy, SWOT and Corporate Finance Report Summary Bioanalytical Systems, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆